Request Demo
Recent blog posts
Latest Hotspot
8 min read
Ivonescimab Biologics Sequence Review Report 2026: PD-1×VEGF Similarity and Patent-Risk Signals
21 July 2026
A Biology Modality MCP review of Ivonescimab (AK112/SMT112), covering its PD-1×VEGF sequence architecture, full-chain similarity hits, pairwise alignments, patent families and diligence priorities.
Latest Hotspot
8 min read
Low-grade serous ovarian cancer Indication Strategy Report 2026: MEK1, Trials and Deals
21 July 2026
Low-grade serous ovarian cancer indication strategy report covering epidemiology, MEK1 biology, active trials, competition and deal signals using PatSnap MCP...
Latest Hotspot
8 min read
Gestational trophoblastic neoplasia Indication Strategy Report 2026: VEGF-A, Trials and Deals
21 July 2026
Gestational trophoblastic neoplasia indication strategy report covering epidemiology, VEGF-A biology, active trials, competition and deal signals using PatSnap...
Latest Hotspot
8 min read
Vulvar squamous cell carcinoma Indication Strategy Report 2026: PD-1, Trials and Deals
21 July 2026
Vulvar squamous cell carcinoma indication strategy report covering epidemiology, PD-1 biology, active trials, competition and deal signals using PatSnap MCP...
Latest Hotspot
8 min read
Penile squamous cell carcinoma Indication Strategy Report 2026: EGFR, Trials and Deals
21 July 2026
Penile squamous cell carcinoma indication strategy report covering epidemiology, EGFR biology, active trials, competition and deal signals using PatSnap MCP...
Latest Hotspot
8 min read
Renal medullary carcinoma Indication Strategy Report 2026: INI1, Trials and Deals
21 July 2026
Renal medullary carcinoma indication strategy report covering epidemiology, INI1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Chromophobe renal cell carcinoma Indication Strategy Report 2026: FLCN, Trials and Deals
21 July 2026
Chromophobe renal cell carcinoma indication strategy report covering epidemiology, FLCN biology, active trials, competition and deal signals using PatSnap MCP...
Latest Hotspot
8 min read
Papillary renal cell carcinoma Indication Strategy Report 2026: c-Met, Trials and Deals
21 July 2026
Papillary renal cell carcinoma indication strategy report covering epidemiology, c-Met biology, active trials, competition and deal signals using PatSnap MCP...
Latest Hotspot
8 min read
Paraganglioma Indication Strategy Report 2026: SDHB, Trials and Deals
21 July 2026
Paraganglioma indication strategy report covering epidemiology, SDHB biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Pheochromocytoma Indication Strategy Report 2026: HIF-2α, Trials and Deals
21 July 2026
Pheochromocytoma indication strategy report covering epidemiology, HIF-2α biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Adrenocortical carcinoma Indication Strategy Report 2026: IGF-1R, Trials and Deals
21 July 2026
Adrenocortical carcinoma indication strategy report covering epidemiology, IGF-1R biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Medullary thyroid carcinoma Indication Strategy Report 2026: RET, Trials and Deals
21 July 2026
Medullary thyroid carcinoma indication strategy report covering epidemiology, RET biology, active trials, competition and deal signals using PatSnap MCP evidence.